psalexa
logo

Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline Analysis, 2017

Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: November 2017
Report Code: LS11314
Available Format:
Pages: 71

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

PSP occurs when excess Tau protein damages the brain cells and is a supranuclear disease, since it damages the nuclei that control eye movements. The common symptoms of the disease are loss of balance, fast walking, bumping into objects or people, falling, dementia, slurring of speech, difficulty in swallowing, poor working of eyelids, sleep disruption, urinary incontinence, and constipation. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scan are used as testing procedures for PSP diagnosis. AbbVie Inc. is in the process of developing ABBV-8E12 for the treatment of the disease. Many companies are more focused on developing their drug candidates as small molecule with the oral route of administration in the PSP therapeutics pipeline. No medication is effective in halting the progression of the disease however, several medications, including dopamine agonists, tricyclic antidepressants, and methysergide, may provide modest symptomatic improvement.

 

PROGRESSIVE SUPRANUCLEAR PALSY THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

PROGRESSIVE SUPRANUCLEAR PALSY THERAPEUTICS

Pipeline Analysis

As of November 2017, the PSP therapeutics pipeline comprises of approximately 14 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of PSP include AbbVie Inc., Biogen Inc., Asceneuron SA, Intellect Neurosciences, Inc. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry